Health
New targets for the development of a drug treatment for obesity and type 2 diabetes – Medical Xpress
The GIP receptor in the central nervous system plays a crucial role in the regulation of body weight and food intake. This is shown by a recent study by Helmholtz…
The GIP receptor in the central nervous system plays a crucial role in the regulation of body weight and food intake. This is shown by a recent study by Helmholtz Zentrum München, ETH Zurich and the German Center for Diabetes Research (DZD). The study, which has now been published in Cell Metabolism, identifies new targets for the development of a drug treatment for obesity and type 2 diabetes.
Dual-agonists targeting the receptors for Glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic…
-
Business22 hours agoBattle of the ASX ETFs: Why has VGS outperformed VTS this year?
-
Business21 hours ago5 things to watch on the ASX 200 on Monday 7 April 2025
-
Noosa News18 hours agoMeasles alert: Australia Zoo, Hospital ED, Sushi Hub, Holey Moley Mini Golf and train stations among QLD infection sites
-
Business18 hours ago1 ASX dividend stock down 43% I’d buy right now